Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
Recruiting · NCT07091526 · Observational (researchers observe without assigning treatment) · Lead sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
View the official record on ClinicalTrials.gov →Interventions studied
serum uric acid test
What this trial is about
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Who can take part
Age range
18 Years to 85 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with pathologically confirmed pancreatic cancer (primary)
- Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
- The postoperative survival time was at least 6 weeks
Exclusion criteria
- No surgery was performed, or only palliative surgery/ biopsy was performed
- Patients who underwent emergency hemodialysis or plasma exchange after surgery
- History of gout or long-term urate-lowering therapy, such as allopurinol
- Patients are missing follow-up data
- Hydrochlorothiazide and furosemide were used
- Chronic kidney disease
- Oncolytic syndrome
- Hemolytic anemia
- Lead poisoning
- Hyperparathyroidism
- Hypothyroidism
- A tyrosinase inhibitor was used
- Patients with nonpancreatic primary tumors
- Pregnant or postpartum women.
Where it is running
1 location listed.
- Hepatopancreatobiliary Surgery Institute of Gansu Province - Lanzhou, Gansu, China